Clinical Chinese Medicine Teaching and Research Office, Hebei University of Chinese Medicine, Shijiazhuang, China.
Department of 2nd Nephrology, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China.
Clin Ther. 2023 Sep;45(9):913-920. doi: 10.1016/j.clinthera.2023.07.009. Epub 2023 Aug 17.
The effect of vitamin D effect on glucose markers and obesity in postmenopausal women remains controversial. The current literature contains little information on vitamin D dosage and duration for optimal efficacy in postmenopausal women. This meta-analysis was undertaken to assess the impact of vitamin D on glucose markers and obesity in postmenopausal women.
A number of databases were used dated up to January 5, 2023, with no language restrictions (PubMed/MEDLINE, Web of Science, EMBASE, and Scopus). Treatment response from baseline was estimated from the mean within-group analysis, and SDs were used to calculate the treatment response.
Nine eligible articles with 12 comparisons qualified for the final quantitative analysis. An overall decrease was noted in fasting blood glucose (weighted mean difference [WMD], -3.56 mg/dL; 95% CI, -5.49 to -1.64; P < 0.001), homeostatic model assessment for insulin resistance (WMD, -1.168 mm; 95% CI, -2.001 to -0.33; P = 0.006), insulin (WMD, -2.26 units; 95% CI, -4.35 to -0.18; P = 0.033), and glycosylated hemoglobin (WMD, -0.41%; 95% CI, -0.54 to -0.29; P < 0.001) after vitamin D administration in postmenopausal women. In subgroup analyses, a notable decrease in fasting blood glucose was detected when the intervention course was ˃6 months and dosage ≤1000 IU/d (WMD, -3.48 mg/dL). The present study showed that vitamin D was not associated with body mass index, body weight, or waist circumference in postmenopausal women.
Vitamin D is beneficial for glucose markers but not obesity in postmenopausal women. An individualized dosage regimen of vitamin D should be followed depending on the clinical outcome target of postmenopausal women.
维生素 D 对绝经后妇女葡萄糖标志物和肥胖的影响仍存在争议。目前的文献中关于维生素 D 剂量和持续时间以达到最佳疗效的信息很少。本荟萃分析旨在评估维生素 D 对绝经后妇女葡萄糖标志物和肥胖的影响。
使用了多个数据库，检索日期截至 2023 年 1 月 5 日，无语言限制（PubMed/MEDLINE、Web of Science、EMBASE 和 Scopus）。采用组内均值分析估计从基线开始的治疗反应，并用标准差计算治疗反应。
9 篇符合条件的文章共 12 项比较纳入最终的定量分析。空腹血糖（加权均数差值 [WMD]，-3.56 mg/dL；95%CI，-5.49 至-1.64；P < 0.001）、稳态模型评估的胰岛素抵抗（WMD，-1.168 mm；95%CI，-2.001 至-0.33；P = 0.006）、胰岛素（WMD，-2.26 单位；95%CI，-4.35 至-0.18；P = 0.033）和糖化血红蛋白（WMD，-0.41%；95%CI，-0.54 至-0.29；P < 0.001）在绝经后妇女中接受维生素 D 治疗后均有显著降低。在亚组分析中，当干预疗程>6 个月且剂量≤1000 IU/d 时，空腹血糖显著降低（WMD，-3.48 mg/dL）。本研究表明，维生素 D 与绝经后妇女的体重指数、体重或腰围无关。
维生素 D 对绝经后妇女的葡萄糖标志物有益，但对肥胖无益。应根据绝经后妇女的临床结局目标制定个体化的维生素 D 剂量方案。
